IDXX:NASDAQIDEXX Laboratories, Inc. Analysis

IDEXX Laboratories has delivered a stellar 39.4% price appreciation over the past year, driven by robust revenue growth of 14.3% and exceptional profitability (gross margin ~62%, operating margin ~30%). Financial strength is underscored by a 66% ROE, healthy operating cash flow, and a solid free cash flow generation. However, the stock trades at a DCF‑derived fair value of $239 versus a market price of $610, reflecting a PE of 46.7 versus the industry average of 25.4, indicating significant overvaluation. Technicals show a neutral trend, with the price sitting just above the support level of $594, a bearish MACD histogram, and an RSI of 37 suggesting mild oversold conditions, while volume is increasing. Analyst sentiment remains positive (13 analysts, median target $775), but the valuation gap and heightened volatility (32% 30‑day) warrant caution.